BLA 761149 · Genentech
Enspryng
Satralizumab · Injection
NovelBreakthrough therapyOrphanLast checked: Nov 20, 2026Latest source record: Oct 15, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2020
Aug 14, 2020
Approved uses
2
Original approval plus efficacy supplements
Registered trials
15
9 Phase 3, 6 recruiting
FAERS reports
1,789
1,398 serious, 102 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 23, 2026.
ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for: the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients. ( 1.2 ) 1.1 Neuromyelitis Optica Spectrum Disorder (NMOSD) ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. 1.2 Thyroid Eye Disease (TED) ENSPRYNG is indicated for the treatment of thyroid eye disease (TED) regardless of TED activity or duration in adult patients.
Mechanism: The precise mechanism by which satralizumab-mwge exerts therapeutic effects in NMOSD and TED is unknown but is presumed to involve inhibition of IL-6-mediated signaling through binding to soluble and membrane-bound IL-6 receptors.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 15, 2026 Supplement 8 · Efficacy · priority review LetterLabelMedication Guide
- Aug 14, 2020 Original approval · Type 1 - New Molecular Entity NovelBreakthrough therapyOrphanLabelLetterReview
1 products under this application
- ENSPRYNG · SATRALIZUMAB 120MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Satralizumab" as an intervention, any sponsor and status, largest first.
- Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSDPivotal-lookingRecruiting
Massachusetts General HospitalAcademic, hospital or other
NCT07010302 · 540 participants (planned) · Start Sep 1, 2026 · Primary completion Jan 2030
Drug: Rituximab (R); Eculizumab (Soliris®) and 3 more · For: NMOSD
Sites: Boston, Massachusetts; Berlin, Germany · 3 sites in all
- A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia GravisPivotal-lookingTerminated
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04963270 · 188 participants · Start Oct 19, 2021 · Primary completion Jan 29, 2024
Drug: Satralizumab · For: Generalized Myasthenia Gravis
Sites: Los Angeles, California; Orange, California; Pasadena, California · 76 sites in all
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseasePivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05271409 · 139 participants · Start Aug 30, 2022 · Primary completion Nov 20, 2025
Drug: Satralizumab · For: Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD)
Sites: Birmingham, Alabama; Irvine, California; Aurora, Colorado · 53 sites in all
- Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseasePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05987423 · 131 participants · Start Oct 26, 2023 · Primary completion Jul 8, 2025
Drug: Satralizumab; Placebo · For: Thyroid Eye Disease; TED
Sites: Beverly Hills, California; La Jolla, California; Wichita, Kansas · 46 sites in all
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants With Thyroid Eye DiseasePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06106828 · 127 participants · Start Nov 15, 2023 · Primary completion Jul 24, 2025
Drug: Satralizumab; Placebo · For: Thyroid Eye Disease
Sites: San Diego, California; Danbury, Connecticut; Chicago, Illinois · 41 sites in all
- A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05503264 · 122 participants · Start Sep 27, 2022 · Primary completion Dec 16, 2026
Drug: Satralizumab · For: NMDAR Autoimmune Encephalitis; LGI1 Autoimmune Encephalitis
Sites: Birmingham, Alabama; Newport Beach, California; San Francisco, California · 56 sites in all
- A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT04660539 · 119 participants · Start Mar 2, 2021 · Primary completion May 28, 2024
Drug: satralizumab; azathioprine (AZA) and 2 more · For: Neuromyelitis Optica Spectrum Disorder
Sites: Birmingham, Alabama; Miami, Florida; Columbus, Georgia · 53 sites in all
- Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)Pivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02073279 · 95 participants · Start Aug 5, 2014 · Primary completion Oct 12, 2018
Drug: Satralizumab; Placebo · For: Neuromyelitis Optica (NMO); NMO Spectrum Disorder (NMOSD)
Sites: Aurora, Colorado; Miami, Florida; Vero Beach, Florida · 58 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neuromyelitis optica spectrum disorder305
- off label use176
- urinary tract infection140
- pneumonia114
- covid-1975
- no adverse event75
- fatigue66
- hypoaesthesia56
- infection56
- headache54
- pain49
- arthralgia46
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2014 | 1 |
| 2020 | 12 |
| 2021 | 130 |
| 2022 | 210 |
| 2023 | 343 |
| 2024 | 373 |
| 2025 | 403 |
| 2026 | 317 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Enspryng (Satralizumab-Mwge)
2024 spending
$45.3M
Beneficiaries
267
2,251 claims
Per beneficiary
$169,561
$16,755.31 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $968,468 |
| 2021 | $12,327,698 |
| 2022 | $24,033,810 |
| 2023 | $33,897,861 |
| 2024 | $45,272,835 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T, Kleiter I, Fujihara K, et al. · N Engl J Med 2019 · Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A, Greenberg BM, Bennett JL, et al. · Lancet Neurol 2020 · Clinical Trial, Phase III, Multicenter Study
- Immunotherapies in neuromyelitis optica: Bayesian network meta-analysis.
John N, Lim A, Sunthar SR, et al. · J Neurol 2025 · Network Meta-Analysis
- Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Habib AA, Zhao C, Aban I, et al. · Lancet Neurol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Long-Term Efficacy and Safety of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disorder From the SAkuraMoon Open-Label Extension Study.
Bennett JL, Fujihara K, Saiz A, et al. · Neurol Neuroimmunol Neuroinflamm 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- A systematic literature review informing the consensus statement on efficacy and safety of pharmacological treatment with interleukin-6 pathway inhibition with biological DMARDs in immune-mediated inflammatory diseases.
Kastrati K, Aletaha D, Burmester GR, et al. · RMD Open 2022 · Research Support, Non-U.S. Gov't, Systematic Review
Sponsor: Roche (Genentech)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.